Computational approaches to virtual screening in human central nervous system therapeutic targets

In the past several years of drug design, advanced high-throughput synthetic and analytical chemical technologies are continuously producing a large number of compounds. These large collections of chemical structures have resulted in many public and commercial molecular databases. Thus, the availability of larger data sets provided the opportunity for developing new knowledge mining or virtual screening (VS) methods. Therefore, this research work is motivated by the fact that one of the main interests in the modern drug discovery process is the development of new methods to predict compounds with large therapeutic profiles (multi-targeting activity), which is essential for the discovery of novel drug candidates against complex multifactorial diseases like central nervous system (CNS) disorders. This work aims to advance VS approaches by providing a deeper understanding of the relationship between chemical structure and pharmacological properties and design new fast and robust tools for drug designing against different targets/pathways. To accomplish the defined goals, the first challenge is dealing with big data set of diverse molecular structures to derive a correlation between structures and activity. However, an extendable and a customizable fully automated in-silico Quantitative-Structure Activity Relationship (QSAR) modeling framework was developed in the first phase of this work. QSAR models are computationally fast and powerful tool to screen huge databases of compounds to determine the biological properties of chemical molecules based on their chemical structure. The generated framework reliably implemented a full QSAR modeling pipeline from data preparation to model building and validation. The main distinctive features of the designed framework include a)efficient data curation b) prior estimation of data modelability and, c)an-optimized variable selection methodology that was able to identify the most biologically relevant features responsible for compound activity. Since the underlying principle in QSAR modeling is the assumption that the structures of molecules are mainly responsible for their pharmacological activity, the accuracy of different structural representation approaches to decode molecular structural information largely influence model predictability. However, to find the best approach in QSAR modeling, a comparative analysis of two main categories of molecular representations that included descriptor-based (vector space) and distance-based (metric space) methods was carried out. Results obtained from five QSAR data sets showed that distance-based method was superior to capture the more relevant structural elements for the accurate characterization of molecular properties in highly diverse data sets (remote chemical space regions). This finding further assisted to the development of a novel tool for molecular space visualization to increase the understanding of structure-activity relationships (SAR) in drug discovery projects by exploring the diversity of large heterogeneous chemical data. In the proposed visual approach, four nonlinear DR methods were tested to represent molecules lower dimensionality (2D projected space) on which a non-parametric 2D kernel density estimation (KDE) was applied to map the most likely activity regions (activity surfaces). The analysis of the produced probabilistic surface of molecular activities (PSMAs) from the four datasets showed that these maps have both descriptive and predictive power, thus can be used as a spatial classification model, a tool to perform VS using only structural similarity of molecules. The above QSAR modeling approach was complemented with molecular docking, an approach that predicts the best mode of drug-target interaction. Both approaches were integrated to develop a rational and re-usable polypharmacology-based VS pipeline with improved hits identification rate. For the validation of the developed pipeline, a dual-targeting drug designing model against Parkinson’s disease (PD) was derived to identify novel inhibitors for improving the motor functions of PD patients by enhancing the bioavailability of dopamine and avoiding neurotoxicity. The proposed approach can easily be extended to more complex multi-targeting disease models containing several targets and anti/offtargets to achieve increased efficacy and reduced toxicity in multifactorial diseases like CNS disorders and cancer. This thesis addresses several issues of cheminformatics methods (e.g., molecular structures representation, machine learning, and molecular similarity analysis) to improve and design new computational approaches used in chemical data mining. Moreover, an integrative drug-designing pipeline is designed to improve polypharmacology-based VS approach. This presented methodology can identify the most promising multi-targeting candidates for experimental validation of drug-targets network at the systems biology level in the drug discovery process

QSAR METHODS DEVELOPMENT, VIRTUAL AND EXPERIMENTAL SCREENING FOR CANNABINOID LIGAND DISCOVERY

G protein coupled receptors (GPCRs) are the largest receptor family in mammalian genomes and are known to regulate wide variety of signals such as ions, hormones and neurotransmitters. It has been estimated that GPCRs represent more than 30% of current drug targets and have attracted many pharmaceutical industries as well as academic groups for potential drug discovery. Cannabinoid (CB) receptors, members of GPCR superfamily, are also involved in the activation of multiple intracellular signal transductions and their endogenous ligands or cannabinoids have attracted pharmacological research because of their potential therapeutic effects. In particular, the cannabinoid subtype-2 (CB2) receptor is known to be involved in immune system signal transductions and its ligands have the potential to be developed as drugs to treat many immune system disorders without potential psychotic side-effects. Therefore, this work was focused on discovering novel CB2 ligands by developing novel quantitative structure-activity relationship (QSAR) methods and performing virtual and experimental screenings. Three novel QSAR methods were developed to predict biological activities and binding affinities of ligands. In the first method, a traditional fragment-based approach was improved by introducing a fragment similarity concept that enhanced the prediction accuracy remarkably. In the second method, pharmacophoric and morphological descriptors were incorporated to derive a novel QSAR regression model with good prediction accuracy. In the third method, a novel fingerprint-based artificial neural network QSAR model was developed to overcome the similar scaffold requirement of many fragment-based and other 3D-QSAR methods. These methods provide a foundation for virtual screening and hit ranking of chemical ligands from large chemical space. In addition, several novel CB2 selective ligands within nM binding affinities were discovered. These ligands were proven to be inverse agonists as validated by functional assays and could be useful probes to study CB2 signaling as well as potential drug candidates for autoimmune disesases

IN SILICO METHODS FOR DRUG DESIGN AND DISCOVERY

Computer-aided drug design (CADD) methodologies are playing an ever-increasing role in drug discovery that are critical in the cost-effective identification of promising drug candidates. These computational methods are relevant in limiting the use of animal models in pharmacological research, for aiding the rational design of novel and safe drug candidates, and for repositioning marketed drugs, supporting medicinal chemists and pharmacologists during the drug discovery trajectory.Within this field of research, we launched a Research Topic in Frontiers in Chemistry in March 2019 entitled “In silico Methods for Drug Design and Discovery,” which involved two sections of the journal: Medicinal and Pharmaceutical Chemistry and Theoretical and Computational Chemistry. For the reasons mentioned, this Research Topic attracted the attention of scientists and received a large number of submitted manuscripts. Among them 27 Original Research articles, five Review articles, and two Perspective articles have been published within the Research Topic. The Original Research articles cover most of the topics in CADD, reporting advanced in silico methods in drug discovery, while the Review articles offer a point of view of some computer-driven techniques applied to drug research. Finally, the Perspective articles provide a vision of specific computational approaches with an outlook in the modern era of CADD

Multi-target selection and high throughput quantitative structure-activity relationship model development

Ph.DDOCTOR OF PHILOSOPH

Developing and validating predictive decision tree models from mining chemical structural fingerprints and high–throughput screening data in PubChem

<p>Abstract</p> <p>Background</p> <p>Recent advances in high-throughput screening (HTS) techniques and readily available compound libraries generated using combinatorial chemistry or derived from natural products enable the testing of millions of compounds in a matter of days. Due to the amount of information produced by HTS assays, it is a very challenging task to mine the HTS data for potential interest in drug development research. Computational approaches for the analysis of HTS results face great challenges due to the large quantity of information and significant amounts of erroneous data produced.</p> <p>Results</p> <p>In this study, Decision Trees (DT) based models were developed to discriminate compound bioactivities by using their chemical structure fingerprints provided in the PubChem system <url>http://pubchem.ncbi.nlm.nih.gov</url>. The DT models were examined for filtering biological activity data contained in four assays deposited in the PubChem Bioassay Database including assays tested for 5HT1a agonists, antagonists, and HIV-1 RT-RNase H inhibitors. The 10-fold Cross Validation (CV) sensitivity, specificity and Matthews Correlation Coefficient (MCC) for the models are 57.2~80.5%, 97.3~99.0%, 0.4~0.5 respectively. A further evaluation was also performed for DT models built for two independent bioassays, where inhibitors for the same HIV RNase target were screened using different compound libraries, this experiment yields enrichment factor of 4.4 and 9.7.</p> <p>Conclusion</p> <p>Our results suggest that the designed DT models can be used as a virtual screening technique as well as a complement to traditional approaches for hits selection.</p

Computational Approaches: Drug Discovery and Design in Medicinal Chemistry and Bioinformatics

This book is a collection of original research articles in the field of computer-aided drug design. It reports the use of current and validated computational approaches applied to drug discovery as well as the development of new computational tools to identify new and more potent drugs

A QSTR-based expert system to predict sweetness of molecules

This work describes a novel approach based on advanced molecular similarity to predict the sweetness of chemicals. The proposed Quantitative Structure-Taste Relationship (QSTR) model is an expert system developed keeping in mind the five principles defined by the Organization for Economic Co-operation and Development (OECD) for the validation of (Q)SARs. The 649 sweet and non-sweet molecules were described by both conformation-independent extended-connectivity fingerprints (ECFPs) and molecular descriptors. In particular, the molecular similarity in the ECFPs space showed a clear association with molecular taste and it was exploited for model development. Molecules laying in the subspaces where the taste assignation was more difficult were modeled trough a consensus between linear and local approaches (Partial Least Squares-Discriminant Analysis and N-nearest-neighbor classifier). The expert system, which was thoroughly validated through a Monte Carlo procedure and an external set, gave satisfactory results in comparison with the state-of-the-art models. Moreover, the QSTR model can be leveraged into a greater understanding of the relationship between molecular structure and sweetness, and into the design of novel sweeteners.Instituto de Investigaciones Fisicoquímicas Teóricas y AplicadasFacultad de Ciencias Exacta

Development and Extension of Cheminformatics Techniques for Integration of Diverse Data to Enhance Drug Discovery

The scientific community has fallen headlong into the age of data. With the available crop of information available to scientists growing at an exponential pace, tools to harvest this data and process it into knowledge are needed. This blanket statement is nowhere more true than in drug discovery today. The increasing quantities of bioactivity and protein crystallographic data provide key information capable of improving the state of virtual screening. The CoLiBRI methodology attempts to learn from the large knowledge base of protein-ligand interactions to discover a comprehensive model capable of filtering large libraries very quickly using only a protein structure. This modeling procedure has been greatly expanded to encompass a wide range of descriptor techniques and to use advanced statistical methods of multidimensional mapping. The growth of virtual screening methods (including CoLiBRI) has provided a plethora of options to cheminformaticians with little guidance on their strengths and weaknesses. This oversight in methodology benchmarking should be addressed to reduce the time and effort wasted applying subpar screening protocols. To attend to this issue, we developed a benchmark dataset that will enable a flood of methodology experimentation and validation. The recent generation of gene expression data and cancer cell growth inhibition data enable identification of signatures of cellular resistance. These signatures can be used as validated prognostic markers to guide patient management thereby fueling the personalization of cancer treatment. From the available data, we have derived hypothetical biomarkers of multidrug resistance and a flood of links between gene expression and chemical specific resistance that require experimental validation. The increasing capabilities of cheminformatics techniques require dissemination to the public to produce the greatest impact. We have therefore developed a web portal providing cheminformatics software and models to fuel public drug discovery efforts